Compare AEC & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEC | LONA |
|---|---|---|
| Founded | 1989 | 2011 |
| Country | Canada | United States |
| Employees | 15 | 19 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.9M | 76.8M |
| IPO Year | N/A | N/A |
| Metric | AEC | LONA |
|---|---|---|
| Price | $4.95 | $8.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 44.7K | 27.4K |
| Earning Date | 05-01-2015 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.66 | $4.21 |
| 52 Week High | $12.49 | $14.21 |
| Indicator | AEC | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 60.49 | 39.98 |
| Support Level | $4.94 | $8.12 |
| Resistance Level | $5.27 | $11.44 |
| Average True Range (ATR) | 0.39 | 0.60 |
| MACD | 0.08 | -0.08 |
| Stochastic Oscillator | 95.97 | 16.59 |
Anfield Energy Inc is a mineral exploration and development company. This company focuses on uranium and vanadium development and near-term production. The exploration project of the company includes Shootaring Canyon Mill and Velvet-Wood and Slick Rock Uranium Project from Uranium One and The West Slope Project located in Montrose and San Miguel Counties in southwestern Colorado. The company's geographical segments are Canada and the United States.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.